| Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy Y Liu, J Zugazagoitia, FS Ahmed, BS Henick, SN Gettinger, RS Herbst, ... Clinical cancer research 26 (4), 970-977, 2020 | 265 | 2020 |
| Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response M Sahraei, B Chaube, Y Liu, J Sun, A Kaplan, NL Price, W Ding, ... The Journal of clinical investigation 129 (12), 5518-5536, 2019 | 111 | 2019 |
| Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations MI Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ... Journal of Thoracic Oncology 13 (12), 1884-1896, 2018 | 90 | 2018 |
| Biomarkers associated with beneficial PD-1 checkpoint blockade in non–small cell lung cancer (NSCLC) identified using high-Plex digital spatial profiling J Zugazagoitia, S Gupta, Y Liu, K Fuhrman, S Gettinger, RS Herbst, ... Clinical Cancer Research 26 (16), 4360-4368, 2020 | 89 | 2020 |
| Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non–small cell lung cancer J Zugazagoitia, Y Liu, M Toki, J McGuire, FS Ahmed, BS Henick, R Gupta, ... Journal of Thoracic Oncology 14 (12), 2084-2096, 2019 | 57 | 2019 |
| Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement S Bellone, N Buza, J Choi, L Zammataro, L Gay, J Elvin, DL Rimm, Y Liu, ... Clinical Cancer Research 24 (14), 3282-3291, 2018 | 53 | 2018 |
| Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry T MacNeil, IA Vathiotis, S Martinez-Morilla, V Yaghoobi, J Zugazagoitia, ... Biotechniques 69 (6), 460-468, 2020 | 39 | 2020 |
| Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non–small cell lung cancer IJ Datar, SC Hauc, S Desai, N Gianino, B Henick, Y Liu, K Syrigos, ... Clinical Cancer Research 27 (10), 2837-2847, 2021 | 25 | 2021 |
| Association of PD-1/PD-L1 co-location with immunotherapy outcomes in non–small cell lung cancer N Gavrielatou, Y Liu, I Vathiotis, J Zugazagoitia, TN Aung, S Shafi, ... Clinical Cancer Research 28 (2), 360-367, 2022 | 19 | 2022 |
| Advances in quantitative immunohistochemistry and their contribution to breast cancer V Yaghoobi, S Martinez-Morilla, Y Liu, L Charette, DL Rimm, M Harigopal Expert Review of Molecular Diagnostics 20 (5), 509-522, 2020 | 17 | 2020 |
| Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations. M Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ... Journal of Clinical Oncology 35 (15_suppl), 9076-9076, 2017 | 7 | 2017 |
| quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes M Toki, J Zugazagoitia, M Altan, L Liu, N Mani, Y Liu, K Syrigos, L Chen, ... Cancer research 79 (13_Supplement), 3151-3151, 2019 | 5 | 2019 |
| Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations MI Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ... Journal of thoracic oncology: official publication of the International …, 2018 | 4 | 2018 |
| Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients Y Liu, J Zugazagoitia, B Henick, KA Schalper, DL Rimm Cancer Research 79 (13_Supplement), 2674-2674, 2019 | 1 | 2019 |
| High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence MI Toki, PF Wong, H Kluger, Y Liu, C Merritt, G Ong, S Warren, ... Cancer Research 78 (13_Supplement), 3621-3621, 2018 | 1 | 2018 |
| Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC Y Liu, J Zugazagoitia, KA Schalper, RS Herbst, DL Rimm Cancer Research 80 (16_Supplement), 2002-2002, 2020 | | 2020 |
